These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sialyl Tn as a prognostic marker in epithelial ovarian cancer. Kobayashi H; Terao T; Kawashima Y Br J Cancer; 1992 Nov; 66(5):984-5. PubMed ID: 1419648 [No Abstract] [Full Text] [Related]
6. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. Bast R; Woolas R BMJ; 1993 Jun; 306(6893):1684-5. PubMed ID: 8324445 [No Abstract] [Full Text] [Related]
7. Report of BACR workshop on monoclonal antibodies in breast and ovarian cancer, Brasenose College, Oxford March 17-19th 1991. Leonard RC; Fisken J; Roulston JE Br J Cancer; 1991 Oct; 64(4):796-7. PubMed ID: 1911231 [No Abstract] [Full Text] [Related]
8. [CA-12 tumor marker values in serum following radioimmuno-scintigraphy]. Barrada M; Pateisky N; Schatten C; Philipp K; Sevelda P; Vavra N Gynakol Rundsch; 1990; 30 Suppl 1():72-3. PubMed ID: 2079306 [No Abstract] [Full Text] [Related]
9. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196 [TBL] [Abstract][Full Text] [Related]
10. Correlation between breast cancer mucin (BCM) and CA 125 serum levels in patients with active ovarian tumors. Roiz C; Allende T; Fernández-García J; Vivanco J; Bianco A; Ruibal A Int J Biol Markers; 1990; 5(4):207. PubMed ID: 2093735 [No Abstract] [Full Text] [Related]
13. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer]. Kondera-Anasz Z; Mielczarek-Palacz A; Switała J Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121 [TBL] [Abstract][Full Text] [Related]
14. [Comparative studies of the prognostic relevance of tumor markers in ovarian cancer]. Dörffler P; Caffier H Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():293-5. PubMed ID: 8118321 [No Abstract] [Full Text] [Related]
15. Management of patients with ovarian cancer using monoclonal antibodies. Lastoria S; Panza N; Esposito G; Vergara E; Castelli L; Caracò C; Battista C; Pacilio G; Salvatore M Biomed Pharmacother; 1992; 46(10):453-63. PubMed ID: 1306360 [TBL] [Abstract][Full Text] [Related]
16. Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546. Saito M; Aoki D; Susumu N; Suzuki A; Suzuki N; Udagawa Y; Nozawa S Int J Gynecol Cancer; 2005; 15(1):37-44. PubMed ID: 15670295 [TBL] [Abstract][Full Text] [Related]
17. Advanced ovarian cancer. Tumour markers. Rustin GJ; van der Burg ME; Berek JS Ann Oncol; 1993; 4 Suppl 4():71-7. PubMed ID: 8312203 [TBL] [Abstract][Full Text] [Related]
18. [Value of Ca 125 in preoperative diagnosis of adnexa tumors]. Krämer S; Jäger W; Schönwälder A; Wildt L; Lang N Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():48-9. PubMed ID: 8118355 [No Abstract] [Full Text] [Related]
19. CA 15-3 serum levels in ovarian cancer. Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S Oncology; 1988; 45(3):263-7. PubMed ID: 3163419 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker. Onetto M; Bruzzone M; Conte PF; Ruvolo M; Conio A; Chiara S; Falcone A; Bentivoglio G; Serra GE; Paganuzzi M Oncology; 1989; 46(2):117-22. PubMed ID: 2710476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]